Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myeloma-Reference-Cited by-同舟云学术

Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myeloma

Published:2021-12-17 Issue:2 Volume:11 Page:358-370
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Medicine

Author:

Pan Darren¹^ORCID,Kaufman Jonathan L.²,Htut Myo³,Agrawal Manish⁴,Mazumder Amitabha⁵,Cornell Robert F.⁶,Zonder Jeffrey A.⁷,Fay Joseph W.⁸,Modiano Manuel R.⁹,Moshier Erin L.¹⁰,Rush Selena A.¹¹,Tunquist Brian J.¹¹,Chari Ajai¹^ORCID

Affiliation:

1. Tisch Cancer Institute Icahn School of Medicine at Mount Sinai New York New York USA

2. Winship Cancer Institute Emory University Atlanta Georgia USA

3. City of Hope National Medical Center Duarte California USA

4. Maryland Oncology Hematology Columbia Maryland USA

5. The Oncology Institute of Hope and Innovation Glendale California USA

6. Vanderbilt University Medical Center Nashville Tennessee USA

7. Karmanos Cancer Institute Detroit Michigan USA

8. Texas Oncology Baylor Charles A Sammons Cancer Center Dallas Texas USA

9. Arizona Clinical Research Center Hematology Oncology Tucson Arizona USA

10. Department of Population Health Science and Policy Icahn School of Medicine at Mount Sinai New York New York USA

11. Pfizer New York New York USA

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.4451

Reference27 articles.

1. Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage

2. Mcl-1 Stability Determines Mitotic Cell Fate of Human Multiple Myeloma Tumor Cells Treated with the Kinesin Spindle Protein Inhibitor ARRY-520

3. ARRY‐520, a novel KSP inhibitor with potent activity in hematological and taxane‐resistant tumor models;Woessner R;Anticancer Res,2009

4. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-xL is an essential survival protein of human myeloma cells

5. A Phase 1 and 2 study of Filanesib alone and in combination with low-dose dexamethasone in relapsed/refractory multiple myeloma

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Precision medicine for multiple myeloma: The case for translocation (11;14);Cancer Treatment Reviews;2024-11

2. Current Novel Targeted Therapeutic Strategies in Multiple Myeloma;International Journal of Molecular Sciences;2024-06-04

3. Advances in research on potential inhibitors of multiple myeloma;European Journal of Medicinal Chemistry;2023-12

4. A novel antibody-KSP inhibitor conjugate improves KSP inhibitor efficacy in vitro and in vivo;Biomaterials;2023-10

5. Pathogenesis, clinical characteristics and personalized managements of multiple myeloma with chromosome 1 abnormalities;Leukemia & Lymphoma;2023-06-10